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Abstract: Advanced ovarian cancer carries a grim prognosis and development of targeted therapies to
improve outcomes has become an active area of research in this disease. The epidermal growth factor
receptor (EGFR) and HER2/neu have shown to be overexpressed in ovarian cancer and there have been
several clinical trials evaluating anti-EGFR and HER2 therapies in ovarian cancer. Unfortunately, the drugs
have shown minimal efficacy and more recent work has now focused on identifying mechanisms of resistance
and alternative ways of targeting these pathways. This review will discuss the currently published trials with
anti-EGFR and HER2 agents in ovarian cancer and the further directions of study with these pathways.
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Introduction
Ovarian cancer is the leading cause of death from
gynecologic malignancies. Although conventional
chemotherapy and surgery for advanced ovarian cancer have
improved over the years with better outcomes, the majority
of women still die with drug-resistant disease and as such,
there is a critical need for the development of molecular
targeted therapies (1). Anti-angiogenesis therapies, such
as bevacizumab, and poly ADP ribose polymerase (PARP)
inhibitors, have shown substantial anti-tumor activity in
ovarian cancer (1). Given positive preclinical data, much
interest has been dedicated to studying the ErbB signaling
factor pathway in ovarian cancer (1). The ERbB family of
receptor tyrosine kinases has a role in the tumorigenesis of
many types of solid tumors and consists of the epidermal
growth factor receptor (EGFR) (also known as HER1/
ErbB1), human EGFR2 (HER2/neu)/ERbB2, HER3/
ErbB3 and HER4/ErbB4 (2). The four HER receptors
have a key role in cancer and promote tumorigenesis
via cell proliferation, survival, migration, adhesion, and
differentiation. Each receptor is a type I transmembrane
protein consisting of a heavily glycosylated ectodomain,
which contains a ligand binding site, an intracellular
protein-tyrosine kinase catalytic domain, and a tyrosine-
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containing cytoplasmic tail. Post receptor signaling by
activated HERs include four representative pathways: the
Ras-Raf/mitogen activated protein kinase (MAPK) and
signal transducer and activation of transcription (STAT)
pathways that regulate cell proliferation and differentiation,
the phosphoinositidyl-3-kinase (PI3K)/protein kinase B
(AKT)/mammalian target of rapamycin (mTOR) pathway
that is important for cell survival, and the phospholipase Cγ
(PLCγ) pathway that controls calcium-dependent events.
Mutations, gene amplifications, and protein overexpression
of the HER family members are linked to carcinogenesis
(2,3). Overexpression and/or mutations of EGFR and
HER2 are well documented in a variety of solid tumors,
including ovarian cancer, and have therapeutic implications
(4,5). This review will discuss the clinical trials of antiEGFR and HER2-directed therapies in ovarian cancer,
which unfortunately have been largely disappointing and
will review mechanisms of resistance to these targeted
therapies and future directions.
EGFR in ovarian cancer
The epithelial lining of the ovary normally has weak EGFR
expression and in epithelial ovarian carcinoma, EGFR
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overexpression ranges anywhere from 4-100% of cases (3,6).
It has not been consistently shown to correlate with disease
aggressiveness; however, expression is associated with poor
prognosis and decreased therapeutic responsiveness, which has
led to clinical trials of EGFR inhibitors in this disease (3,7-9).
Clinical trials
Small molecule tyrosine kinase inhibitors (TKIs) and
monoclonal antibodies are currently used to block EGFR
activity and have been studied in ovarian cancer (Table 1).
The most common TKI, erlotinib, is an inhibitor of
HER1/EGFR. It is a quinazolinamine with the chemical
name N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4quinazolinamine. It is an orally active, potent, selective
inhibitor of the EGFR tyrosine kinase. It reversibly binds
to the adenosine triphosphate (ATP)-binding site of EGFR
and completely inhibits autophosphorylation by EGFR
tyrosine kinase. This results in blockage of downstream
EGFR signal-transduction pathways, cell-cycle arrest, and
inhibition of angiogenesis (6). There have been several trials
with erlotinib in ovarian cancer.
One of the earliest trials targeting EGFR in ovarian
cancer was a phase II study by Gordon et al., which
evaluated single agent erlotinib in 34 patients with
refractory, recurrent, EGFR positive epithelial ovarian
tumors who had failed taxane and/or platinum-based
chemotherapy. Patients received daily erlotinib for up to
48 weeks or until disease progression or dose-limiting
toxicity. The objective response rate (ORR) was 6% (95%
CI, 0.7-19.7%) and the median overall survival (OS) was
8 months (95% CI, 19.8-53.5%). Notably, patients with a
rash survived significantly longer than those without a rash
(P=0.009) (10). Hirte et al. enrolled 50 patients with local
or advanced recurrent ovarian cancer, stratified by platinum
sensitivity (n=33 in platinum sensitive arm and n=17 in
platinum resistant arm), in a phase II study of erlotinib and
carboplatin. Patients were treated with erlotinib 150 mg
daily and carboplatin AUC 5 every 21 days. The ORR was
57% in the platinum-sensitive arm and 7% in the platinumresistant arm. A total of 71% of archival tumors stained
positive for EGFR and in platinum-sensitive patients with
EGFR-positive tumors, there were 12 responses (60%
ORR) and the responding platinum-resistant patient was
also EGFR positive. The addition of erlotinib was well
tolerated; however, the addition of erlotinib could not
reverse platinum-resistance (11). Erlotinib was combined
with carboplatin and paclitaxel in a phase II study in the
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first-line treatment of ovarian cancer. A total of 56 patients
were enrolled and 36 patients completed six cycles of the
regimen. The primary endpoint, pathologic complete
response (pCR) at surgical reassessment, was 29% and 13%
in optimally and suboptimally debulked disease, respectively.
The primary objective of increasing pCR by two-fold when
compared to historical data was not met and EGFR gene
amplification was not associated with response rate (12). A
small study of six patients previously failing bolus topotecan
evaluated continuous infusion topotecan in combination
with erlotinib. One patient achieved a partial response (PR)
by CA-125 criteria (13).
Recently, Vergote et al. evaluated the efficacy of
maintenance erlotinib in a phase III trial of patients with
a CR, PR, or stable disease (SD) after first line platinumbased chemotherapy for ovarian carcinoma. A total of 835
patients were randomly assigned to receive maintenance
erlotinib for two years or to observation. In an intentionto-treat analysis, the progression free survival (PFS) and
OS were similar between the two groups and this study
showed no benefit of maintenance erlotinib when compared
with standard management. PFS was 12.7 and 12.4 months
in the erlotinib and observation arms, respectively (HR
adjusted for stratification factors, 1.05; 95% CI, 0.90-1.23;
P=0.525). OS was 50.8 and 59.1 months for the erlotinib
and observation arms, respectively (HR, 0.99; 95% CI,
0.81-1.20; P=0.903). Only 25.8% of patients in the erlotinib
arm stopped treatment due to toxicity and 50.1% required
dose modification mainly due to diarrhea or rash. There was
no difference in subgroup analyses and quality of life scores
were in favor of the observation arm (P=0.0102). Archival
tumor tissue was used to evaluate EGFR overexpression
by immunohistochemistry (IHC), EGFR copy number
by fluorescence in situ hybridization (FISH) and perform
EGFR mutation analyses. The 41/248 patients (32.8%)
in the erlotinib arm and 49/248 patients (39.8%) in the
observation arm demonstrated EGFR positivity. There
was no correlation identified between EGFR staining and
any of the clinicopathologic variables. In the erlotinib arm,
there was no association between PFS, OS, and the IHC
staining or FISH score. In the entire cohort, patients who
were positive by FISH did have a worse survival than those
who were negative for FISH (46.1 vs. 67 months; HR, 1.56;
95% CI, 1.01-2.40; P=0.044). This was similarly seen in a
PFS analysis: patients with EGFR positivity by FISH had
a shorter PFS than those who were negative (9.6 vs. 16.1
months; HR, 1.57; 95% CI, 1.11-2.22; P=0.01). In DNA
mutation analysis performed in 318 patients, the following
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Table 1 Trials of anti-EGFR agents in ovarian cancer
Trial

Phase

Patient population (N)

Intervention

Outcomes

TKIs
Gordon et al. (10),

II

single agent erlotinib

Refractory, recurrent, EGFR Daily erlotinib ×48 weeks or

ORR was 6%; median OS 8 months

positive epithelial ovarian

until disease progression or

(95% CI, 19.8-53.5%)

tumors who have failed

dose-limiting toxicity

taxane and/or platinum
based chemotherapy (N=34)
Hirte et al. (11),

II

erlotinib + carboplatin

Local or advanced recurrent Erlotinib 150 mg daily and

ORR was 57% in platinum-sensitive

ovarian cancer; patients

carboplatin AUC 5 every

arm and 7% in platinum-resistant

stratified by platinum

21 days

arm; ORR 60% in platinum-sensitive

sensitivity (N=33 in

patients who were EGFR-positive

platinum-sensitive arm and
N=17 in platinum-resistant
arm)
Blank et al. (12),

Patients with stage III-

Erlotinib 150 mg daily in

pCR at surgical reassessment was

erlotinib + carboplatin

II

IV ovarian cancer within

combination with paclitaxel

29% and 13% in optimally and

+ paclitaxel

12 weeks of initial

175 mg/m2 and carboplatin

suboptimally debulked disease,

cytoreductive surgery or

AUC 5 every 3 weeks for up

respectively*

in the neoadjuvant setting

to six cycles

(N=56)
Warner et al. (13),

II
#

erlotinib + topotecan

Advanced ovarian cancer

Erlotinib 150 mg daily on days One patient achieved PR by CA-125

patients previously failing

1-10 of each 21-day cycle

bolus topotecan (N=6)

and topotecan 0.4 mg/m2

criteria

continuous infusion for
9-10 days every 3 weeks
Vergote et al. (14),

III

maintenance erlotinib

Patients with a CR, PR or

Maintenance erlotinib for

No difference between PFS (12.7

SD after first line platinum-

2 years vs. observation

vs. 12.4 months in erlotinib and

based chemotherapy for

observation arms, respectively,

ovarian carcinoma (N=835)

P=0.525) and OS (50.8 vs.
59.1 months in erlotinib and
observation arms, respectively,
P=0.903) between the two arms

Schilder et al. (15),

II

single agent gefitinib

Patients with recurrent or

Gefitinib 500 mg daily until

PFS 2.17 months and did not meet

persistent epithelial ovarian

progressive disease or

GOG criteria for further study;

or primary peritoneal cancer adverse effects prohibited

four patients with PFS ≥6 months

(N=30)

further therapy

Patients with platinum-

Canertinib 50 or 200 mg daily SD in 34% and 26%

refractory or recurrent

every 21 days on a

ovarian cancer (N=105)

28-day cycle

Patients with relapsed

Cetuximab 400 mg/m2 on day ORR 34.6%; median time to

cetuximab and

platinum-sensitive ovarian

1, then 250 mg/m2 weekly

progression of 9.4+ months (range,

carboplatin

cancer (N=28)

and carboplatin AUC 6 every

0.9-22.2+ months)

Campos et al. (16),

II

canertinib (CI-1033)
EGFR monoclonal antibodies
Secord et al. (17),

II

21 days
Table 1 (continued)
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Table 1 (continued)
Trial
Konner et al. (18),

Phase
II

cetuximab,

Patient population (N)
treatment of stage III/IV
&

carboplatin and

Intervention

Outcomes

Cetuximab 400 mg/m2 on day Median PFS 14 months and PFS at

Patients with initial
ovarian cancer (N=41)

paclitaxel

1 then 250 mg/m2 weekly;

18 months was 38.8%. Combination

paclitaxel

did not prolong PFS when compared

175 mg/m2 and carboplatin

to historical data

AUC 6 every 21 days
Schilder et al. (19),

II

Patients with persistent or

Cetuximab 400 mg/m2 on day One patient achieved a PR; 9 patients

single agent

recurrent ovarian or primary 1 then 250 mg/m2 weekly

had SD; median PFS was 21 months.

cetuximab

peritoneal cancer (N=25)

One year survival rate: 54.8%

Seiden et al. (20),
matuzumab

II

Patients with recurrent,

Matuzumab 800 mg

platinum-refractory, EGFR-

intravenously weekly

No formal responses (RR 0%)

positive ovarian or primary
peritoneal cancer (N=37)
*, only five patients received the regimen as neoadjuvant therapy prior to cytoreduction: three achieved a complete CR, one
patient had SD and one patient did not complete treatment due to medical comorbidities. At surgery after treatment, 4/5 patients
were able to be optimally cytoreduced; #, phase of trial not specified. Trial was closed early due to sponsor’s decision to stop
developing erlotinib in ovarian cancer; &, 41 patients were enrolled, 40 received treatment and were evaluable for toxicity, 38 were
evaluable for PFS. EGFR, epidermal growth factor receptor; TKIs, tyrosine kinase inhibitors; ORR, objective response rate; OS,
overall survival; pCR, pathologic complete; PR, partial response; SD, stable disease; PFS, progression free survival.

mutations were demonstrated: EGFR (n=3); KRAS (n=9);
NRAS (n=2); BRAF (n=2); and PIK3CA (n=12). In patients
with a mutation, the PFS was longer than in those without
a mutation (34 vs. 12.2 months, HR, 0.49, 95% CI, 0.280.88, P=0.015); however, EGFR-related mutations did not
predict for efficacy of erlotinib in the treatment arm (14).
The gynecologic oncology group (GOG) has
performed a series of single agent biologic agent trials
in persistent or recurrent ovarian or primary peritoneal
cancer and has studied gefitinib, another EGFR TKI,
in their ‘biologic queue’. However, there was minimal
activity in 30 patients with recurrent or persistent
epithelial ovarian or primary peritoneal carcinoma treated
with gefitinib. Only four patients experienced a PFS of
≥6 months. The median PFS, 2.17 months, did not meet
the GOG criteria for further study. A total of 42% of
tumors demonstrated EGFR positivity (designated 1+ or
higher by IHC) and the four patients with a prolonged
PFS had tumors with some EGFR positivity. EGFR
mutation analysis was performed in 25 specimens; one
EGFR mutation was detected and interestingly, was in
the one patient who experienced a PR (15). Another
GOG biologics study evaluated canertinib (CI-1033),
a 4-anilinoquinazoline that acts irreversibly at the
ATP binding site of the ErbB receptor family member.
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There was a median PFS of 2.2 months, no CR or PRs
were observed and there was no relationship between
tumor expression of any of the ErbB subtypes, disease
stabilization or OS (16). Lapatinib, a dual EGFR and
HER2 inhibitor, will be described later in the article.
In addition to studies with EGFR TKIs, there have been
studies with an anti EGFR monoclonal antibody, cetuximab
(Table 1). Cetuximab and carboplatin was evaluated in 28
patients with relapsed platinum-sensitive ovarian cancer
with an ORR of 34.6% and a median time to progression
of 9.4+ months (range, 0.9-22.2+ months). Archival tissue
for EGFR expression by IHC showed EGFR positivity
(≥1%) in 26/28 patients and interestingly, the two patients
negative for EGFR both responded to cetuximab. Also of
note, the response rates for patients with EGFR positive
tumors were 60%, 40% and 33% for 1+, 2+ and 3+ EGFR
staining, respectively. The intensity of EGFR staining
was not predictive of response and it was hypothesized
that high intensity may actually predict for resistance to
cetuximab (17). In another phase II study of 40 patients
receiving carboplatin, paclitaxel and cetuximab in the
initial treatment of stage III/IV ovarian cancer, the median
PFS was 14.4 months and PFS at 18 months was 38.8%.
The combination was well tolerated but there was no
prolongation of PFS when compared to historical data (18).
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In a phase II trial of single agent cetuximab in 25 patients
with persistent or recurrent ovarian or primary peritoneal
cancer, one patient achieved a PR, nine patients had SD,
and median PFS was 21 months. This trial did not achieve
the required minimal activity for further study by the
GOG (19). A phase II study of EMD72000 (matuzumab), a
humanized anti-EGFR monoclonal antibody, of 37 heavily
pre-treated platinum-resistant patients did not yield any
responses (20).
HER2 in ovarian cancer
In addition to EGFR, there has been a lot of interest in
investigating HER2 in ovarian cancer but studies have
been disappointing. HER2 expression in epithelial ovarian
cancer is more commonly seen in the serous subtype, in
older patients, patients with advanced stage and high-grade
differentiation (21). Similarly to EGFR, the rates of HER2
overexpression and/or amplification in ovarian cancer are
variable, ranging from 2% to 66% (21,22). HER2 has
been studied as a prognostic factor but with contradictory
results. While some studies have shown that HER2
expression is associated with a worse prognosis, others
have not demonstrated any relationship between HER2
and survival (23-28). There are several anti-HER2 agents
that have been approved for breast cancer which have
been investigated in ovarian cancer as well: trastuzumab, a
humanized monoclonal anti-HER2 antibody, pertuzumab,
a recombinant, humanized monoclonal antibody
directed against HER2 that inhibits ligand-activated
heterodimerization with other HER2 receptors, especially
HER3, and lapatinib, a small molecular dual TKI of HER2
and EGFR (29,30).
Clinical trials
Several clinical trials have evaluated anti-HER2 therapies
in ovarian cancer (Table 2). GOG 160 evaluated single agent
trastuzumab in patients with recurrent or persistent ovarian
or primary peritoneal carcinoma with 2+ or 3+ HER2 IHC
expression. Out of 837 tumors screened, only 95 (11.4%)
showed 2+ or 3+ expression; ultimately, 41 eligible and
assessable patients were treated with trastuzumab. ORR was
7.3% and an additional 16 patients (39%) were found to
have SD with three receiving therapy for over a year. There
was no relationship identified between tumor expression of
HER2 and clinical response, PFS, or OS (31).
Gordon et al. evaluated pertuzumab in a phase II,
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multicenter trial in advanced, refractory ovarian cancer.
A total of 61 patients received a loading dose of 840 mg
of pertuzumab followed by 420 mg every 3 weeks and
62 patients received 1,050 mg every 3 weeks. The primary
endpoint, response rate, was 4.3% (95% CI, 1.7-9.4%).
About 6.8% of patients had SD lasting ≥6 months and ten
patients had a CA-125 reduction of at least 50%. Tumor
biopsies were obtained to assay for HER2 overexpression,
amplification and phosphorylated HER2 (pHER2). A total
of 28.6% of the biopsies were pHER2-positive by ELISA
without amplification and interestingly, these patients had
a better outcome following pertuzumab therapy, compared
to patients who were pHER2-negative (32). Pertuzumab
was then studied in combination with gemcitabine in
patients with recurrent platinum-resistant ovarian, primary
peritoneal or fallopian tube carcinoma where 130 patients
were randomized to gemcitabine and pertuzumab or
placebo. ORR was 13.8% in the gemcitabine/pertuzumab
arm vs. 4.6% in the gemcitabine/placebo arm. There was no
statistically significant difference between PFS and OS in
the two arms. The PFS and OS were 2.9 and 13.0 months
in the gemcitabine/pertuzumab arm, respectively, and 2.6
and 13.1 months in the gemcitabine/placebo arm. (P=0.07
for PFS and P=0.65 for OS). In a biomarker analysis, those
patients receiving pertuzumab who demonstrated low
levels of HER3 mRNA had a lower risk of progression
and trend for reduced risk of death, suggesting that low
HER3 mRNA might be both a predictive and prognostic
marker (33). Pertuzumab was also added to carboplatinbased chemotherapy in patients with platinum-sensitive,
relapsed disease. A total of 149 patients received carboplatin
and paclitaxel or gemcitabine with or without pertuzumab.
There was no significant difference in PFS: 34.1 months for
the combination vs. 37.3 months in the chemotherapy only
arm (HR =1.16; 80% CI, 0.90-1.49; P=0.4487). The median
OS for the combination was 28.2 months and not reached
in the chemotherapy-only arm. The HR for death was 1.02
(P=0.9262) and confirmed that there was no difference
between the two arms. In contrast to the prior trial, there
was no treatment effect of pertuzumab on patients with low
HER3 mRNA (34).
Finally, there have been several studies with lapatinib.
Lapatinib was combined with carboplatin and paclitaxel in
a phase I/II study in patients with stage III or IV relapsed
ovarian cancer with an ORR of 50% in 21 patients (35).
Single agent lapatinib was studied in the GOG biologic
queue in persistent or recurrent disease and failed to show
any objective responses in 25 patients with a median PFS of
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Table 2 Trials of anti-HER2 agents in ovarian cancer
Trial

Phase

Patient population (N)

Intervention

Outcomes

Trastuzumab
Bookman et al. (31),

Patients with recurrent

Trastuzumab 4 mg/kg then

single agent

II

or persistent ovarian

2 mg/kg weekly

trastuzumab

or primary peritoneal

ORR 7.3%; 39% of patients with SD

carcinoma with 2+ or 3+
IHC expression (N=41)
Pertuzumab
Gordon et al. (32),

II

Patients with advanced, Pertuzumab at standard dose*

ORR 4.3% (95% CI, 1.7-9.4%); 6.8% of

refractory ovarian

(N=61); pertuzumab 1,050 mg

patients had SD ≥6 months; 10 patients

cancer (N=123)

every 3 weeks (N=62)

with CA-125 reduction of at least 50%

Patients with recurrent

Gemcitabine 800 mg/m2 on

Median PFS was 2.9 months in gem

gemcitabine +/−

platinum-resistant

days 1, 8 of 21 day cycle plus

+ pertuzumab arm vs. 2.6 months in

pertuzumab

ovarian, primary

placebo or pertuzumab at

gem + placebo arm (adjusted HR 0.66;

peritoneal or fallopian

standard dose

P=0.07); OS similar between the two

single agent
pertuzumab
Makhija et al. (33),

II

tube carcinoma (N=130)

arms; ORR 13.8% in gem + pertuzumab
arm and 4.6% in gem + placebo arm

Kaye et al. (34),

Patients with relapsed,

Carboplatin AUC 5 every 21

No difference in PFS: 34.1 months in

pertuzumab +

II

platinum-sensitive

days + paclitaxel 175 mg/m2

combination arm vs. 37.3 months in

carboplatin-based

ovarian cancer (N=149)

every 21 days or gemcitabine

chemo-only arm (HR 1.16; 80% CI, 0.9-

2

chemotherapy

1,000 mg/m d1, 8 every

1.49; P=0.4487)

21 days and pertuzumab at

No difference in OS (28.2 months in

standard dose

combination arm and not reached in
chemo-only arm); HR for death 1.02
(P=0.9262)

Lapatinib
Rivkin et al. (35),

Patients with stage III

Lapatinib 1,000 mg daily

ORR 50%: 21% CR; 29% PR. SD: 29%,

lapatinib +

or IV relapsed ovarian

+ paclitaxel 60 mg/m2 and

PD: 21%

carboplatin +

cancer (N=25 enrolled;

carboplatin AUC 2 weekly, 3

paclitaxel#

21 evaluable)

weeks out of 4

Patients with recurrent

Lapatinib 1,500 mg daily

Garcia et al. (36),

I/II

II

single agent

or persistent epithelial

lapatinib

ovarian or primary

No objective responses observed;
median PFS 1.8 months

peritoneal carcinoma
(N=25)
Lheureux et al. (37),
lapatinib +

II

Patients with recurrent

Topotecan 3.2 mg/m2 weekly

Objective (partial) response observed in

ovarian cancer (N=39)

and lapatinib 1,250 mg daily

14% of patients

topotecan
*, standard dose of pertuzumab was 840 mg loading dose then 420 mg every 3 weeks; #, data was presented at the 2008 ASCO
Annual Meeting and has not yet been published. ORR, objective response rate; SD, stable disease; PFS, progression free survival;
OS, overall survival; PR, partial response.
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1.8 months (36). In vitro, lapatinib enhances the efficacy of
topotecan and so the combination of the two was explored
in a phase I trial of 37 patients with solid tumors, including
ovarian cancer. SD was seen in 18 patients (38). A phase
II trial in 39 patients of the combination with recurrent
ovarian cancer after first line chemotherapy only had a 14%
PR rate (37).
Identifying mechanisms of resistance and future
directions
Given disappointing clinical trial results with anti-EGFR
and HER2 agents, greater insights into elucidating the
mechanisms of resistance to these therapies and how
they interact with other pathways are clearly needed.
Unfortunately, such studies have been quite limited, which
makes future pursuit of these pathways difficult. EGFR and
HER2 may not be oncogenic drivers in ovarian cancer, as
they are in other solid tumors. This notion is supported by
the clinical trials described above which have not confirmed
EGFR and HER2 as predictive markers. This makes it
difficult to extrapolate the known mechanisms of resistance
from other tumor types to ovarian cancer.
Nevertheless, some mechanisms of resistance have been
identified in ovarian cancer and have mostly focused on
EGFR. One of the most common resistance mechanisms,
which holds true in other tumor types as well, is the
activation of downstream signaling pathways, which can
often make the inhibition of a solitary signal transduction
pathway ineffective. Stimulation of EGFR in the cell
membrane leads to the activation of two different but
interconnected, pivotal pathways: the MAPK/extracellular
signal regulated (MAPK/ERK) pathway and the PI3K/
AKT/mTOR pathway (6,39). These pathways drive cell
proliferation, survival and dissemination (40).
MAPK/ERK pathway
MAPK/ERK pathway activation and subsequent interactions
are highly regulated events that become deregulated in
cancer cells. The pathway begins with the activation of
Ras, which initiates a multistep phosphorylation cascade
that leads to the activation of MAPKs, ERK1, and ERK2
which ultimately regulate the transcription of molecules
that are involved in cell proliferation (41). Patients with
ovarian cancer frequently present with activation of the
MAPK/ERK pathway due to activating mutations of KRAS
or BRAF, which occur early in malignant transformation.
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KRAS and BRAF mutations are found in 27-36% and 3350% of low grade serous ovarian carcinomas (LGSOC),
respectively. KRAS mutations are found in 0-12% of high
grade serous ovarian carcinomas (HGSOC) but BRAF
mutations have not been described in HGSOC (40). These
mutations can dysregulate kinase activity and hyperactivate
the MAPK pathway during the induction and progression
of tumorigenesis (42). The identification of these mutations
has led to clinical trials with targeted BRAF and MEK
inhibitor therapy in ovarian cancer (40). However, this
pathway has not yet been evaluated in combination with
anti-EGFR or HER2 therapy in ovarian cancer; however,
it is still important to note that patients who harbor these
mutations, resulting in pathway activation, may be immune
to anti-EGFR and HER2 therapy as the downstream
pathways are constitutively active. Further research of this
pathway as a marker of resistance to anti EGFR and HER2
therapy is needed to confirm this hypothesis.
PI3K/AKT/mTOR pathway
The PI3K/AKT/mTOR pathway is involved in cellular
motility, proliferation, differentiation, survival and
tumorigenesis. It is activated in approximately 70% of
ovarian cancers, leading to hyperactive signaling cascades.
Some of the most common mechanisms that activate this
pathway are mutations or amplification of PIK3CA, the
catalytic subunit for PI3K, and loss of phosphatase and
tensin homolog (PTEN), a tumor suppressor gene that
normally regulates cell growth, survival, proliferation
and angiogenesis through inhibition of the PI3K/
AKT/mTOR pathway. Somatic changes in PIK3CA are
frequently observed in ovarian cancer with 30.5% of cases
having either alteration. PTEN loss has been reported in
approximately 68% of ovarian cancer (43,44).
Given the limited activity of single agent EGFR TKI
inhibition and the known activity of the PI3K/AKT/mTOR
pathway in ovarian cancer, Glaysher et al. evaluated the
effect of dual inhibition of EGFR and PI3K/mTOR on
primary cell cultures from human ovarian tumors. The
agents tested were TKIs erlotinib and gefitinib, ZSTK474, a
PI3K inhibitor, and sirolimus, an mTOR inhibitor. All were
initially tested as single agents and the majority of ovarian
tumors were resistant to the EGFR inhibitors. The greatest
single agent activity was seen with ZSTK474, suggesting
the importance of PI3K signaling in these tumors. There
was minimal response to sirolimus, which was not surprising
given mTOR inhibitors predominantly elicit a cytostatic,

www.thetcr.org

Transl Cancer Res 2015;4(1):107-117

114

rather than cytotoxic, response (39). However, when the
agents were combined, there was greater synergistic activity
with the combination of EGFR inhibitors with the PI3K
and mTOR inhibitors; the most effective combination was
an EGFR inhibitor and a PI3K inhibitor. Muranen et al.
performed a study where ovarian tumor cells were treated
with BEZ235, a PI3K/mTOR inhibitor, which decreased
phosphorylation of proteins downstream of PI3K and
mTOR and reduced cell proliferation markers. However,
treatment with BEZ235 also induced upregulation and/
or activation of multiple prosurvival proteins: cytoplasmic
kinases, antiapoptotic proteins, transcription factors and
several receptor tyrosine kinases, including EGFR and
HER2. In a subsequent experiment, treatment with BEZ235
and EGFR inhibitors, PD168393 or gefitinib, resulted in
marked cell death, suggesting the synergy of these two
pathways (45).
Similar cross-talk has been demonstrated between
EGFR and the Janus kinase (KAL)/STAT pathway that
mediates the epithelial-mesenchymal transition and
enhances migration (46). Furthermore, the endothelin-1
(ET-1) and the selective endothelin-A-receptor (ETAR),
a G protein coupled receptor, are overexpressed in
ovarian carcinomas. The autocrine ET-1/ETA R axis
triggers several signaling pathways, which are involved
in cell proliferation, survival, angiogenesis and invasion.
ET-1 can transactivate EGFR through a Src-dependent
mechanism. In vitro data showed that ET-1 induced
rapid Src and EGFR phosphorylation and caused an
increase in activation of MAPK and AKT in HEY cells,
an ovarian cancer cell line. Treatment of HEY cells with
gefitinib reduced ET-1 induced Src and EGFR activation;
however, ET-1 mediated MAPK and AKT activation was
incompletely reduced. ZD4054, an endothelin receptor
antagonist, was then combined with gefitinib and resulted
in greater inhibition of all of these pathways, again
suggesting the importance of dual targeting (47).
The data described above clearly is in favor of dual
targeting of pathways. Although this is all preclinical data
so far, ideally, these combinations of anti-EGFR or HER2
therapies and downstream pathway inhibitors will be tested
in clinical trials. This has already been done in breast
cancer with the publication of the BOLERO-3 trial, which
demonstrated the benefit of adding everolimus, an mTOR
inhibitor, to trastuzumab and vinorelbine in patients with
trastuzumab-resistant HER2 positive advanced breast
cancer (48). One note of caution is that the combination
of targeted therapies can result in increased toxicity, which
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must be balanced against quality of life in patients with
advanced disease.
Other mechanisms of resistance
Another proposed mechanism has been resistance to
autophagic cell death upon increased EGFR expression
due to stabilization of the facilitated glucose transporter
sodium/glucose cotransporter 1 (SGLT1) (6). SGLT1
allows cancer cells to uptake glucose, regardless of the level
of extracellular glucose, for their survival (49). The cells
are able to uptake enough glucose for ATP generation,
via glycolysis, which prevents them from dying. As such,
the presence of EGFR maintains the basal intracellular
glucose levels and cells do not undergo autophagic death.
Thus, even in the presence of anti EGFR directed agents,
EGFR may provide tumor cells with an increased survival
capacity. It is hypothesized that inhibition of this function
in combination with anti-EGFR directed agents might be
required to overcome resistance (49).
In preclinical models, EGFR has also been shown to
induce platelet-activating factor (PAF) production, which is
a pro-inflammatory lipid mediator that binds to the PAFreceptor (PAFR) and plays a significant role in oncogenic
transformation, tumor growth, neoangiogenesis, and
metastasis in ovarian cancer. Yu et al. demonstrated that
the epidermal growth factor increases PAF production in
CAOV3 and SKOV3 ovarian cancer cell lines. Although
inhibition of EGFR and/or PAFR blocks PAF production,
crosstalk can occur bi-directionally between EGFR and
PAFR and epidermal growth factor induced PAF production
may result in a positive feedback mechanism that acts on
the PAFR to promote ovarian cancer progression. Dual
inhibition of EGFR and PAFR may be one way to overcome
resistance to anti EGFR directed therapies (50).
Conclusions
EGFR and HER2 expression in ovarian cancer is quite
variable. These targets have been extensively studied with
discouraging results and at this point, there seems to be
little role for anti-EGFR or HER2 directed therapies in
ovarian cancer outside of clinical trials. Studying resistance
mechanisms may help identify why these targets have not
been successful and more ideally, there will be more research
into this area. Current data stresses the importance of
dual targeting with anti-EGFR or HER2 and downstream
pathway inhibitors. There has been some recent work in

www.thetcr.org

Transl Cancer Res 2015;4(1):107-117

Translational Cancer Research, Vol 4, No 1 February 2015

uterine carcinoma demonstrating the preclinical efficacy
of neratinib, a small TKI against EGFR and HER2 (51),
and taselisib, a selective inhibitor of PIK3CA, on PIK3CAmutated and HER2 amplified in uterine serous carcinoma
cell lines and mouse xenografts (52). Hopefully, these drugs
will be evaluated in ovarian cancer as well in the future.
There are still possibilities to ‘salvage’ EGFR and HER2
targeting in ovarian cancer, gain greater insight on how
these pathways contribute to tumorigenesis in this disease
and identify a clinical benefit.
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